Patents by Inventor Bart De Strooper

Bart De Strooper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180230232
    Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.
    Type: Application
    Filed: January 16, 2018
    Publication date: August 16, 2018
    Inventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
  • Patent number: 9908943
    Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.
    Type: Grant
    Filed: September 11, 2013
    Date of Patent: March 6, 2018
    Assignees: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D, VRIJE UNIVERSITEIT BRUSSEL
    Inventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
  • Patent number: 9879233
    Abstract: The present application relates to the field of Parkinson's disease (PD), particularly sporadic PD or PD associated with mutations in the mitochondrial kinase PINK1. A new substrate for this kinase, NdufA10, is identified herein. In Parkinson's disease, this protein is dephosphorylated, which is linked to a loss of mitochondrial membrane potential. It is shown that restoring or mimicking phosphorylation of NdufA10 restores the phenotypic defects associated with Parkinson's disease and is thus a new therapeutic paradigm.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: January 30, 2018
    Assignees: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventors: Bart De Strooper, Patrik Verstreken, Vanessa Morais Epifânio
  • Publication number: 20160237166
    Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.
    Type: Application
    Filed: September 11, 2013
    Publication date: August 18, 2016
    Applicants: VIB VZW, VRIJE UNIVERSITEIT BRUSSEL, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D
    Inventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
  • Publication number: 20150299672
    Abstract: The present application relates to the field of Parkinson's disease (PD), particularly sporadic PD or PD associated with mutations in the mitochondrial kinase PINK1. A new substrate for this kinase, NdufA10, is identified herein. In Parkinson's disease, this protein is dephosphorylated, which is linked to a loss of mitochondrial membrane potential. It is shown that restoring or mimicking phosphorylation of NdufA10 restores the phenotypic defects associated with Parkinson's disease and is thus a new therapeutic paradigm.
    Type: Application
    Filed: November 7, 2013
    Publication date: October 22, 2015
    Applicants: KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D, VIB VZW
    Inventors: Bart DE STROOPER, Patrik VERSTREKEN, Vanessa MORAIS EPIFÂNIO
  • Publication number: 20150301068
    Abstract: The disclosure provides an extracellular target for Alzheimer's disease selected from the tetraspanin web family. The disclosure also provides diagnostic methods for the use as a target for detection of Alzheimer's disease in a subject. In addition, screening methods are provided for selecting compounds that bind or down-regulate the expression of the target.
    Type: Application
    Filed: January 29, 2013
    Publication date: October 22, 2015
    Inventors: Bart DE STROOPER, Francesc GUIX
  • Publication number: 20150071940
    Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.
    Type: Application
    Filed: September 11, 2013
    Publication date: March 12, 2015
    Applicants: VIB VZW, VRIJE UNIVERSITEIT BRUSSEL, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D
    Inventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
  • Patent number: 8956614
    Abstract: The present invention relates to antibodies with a specificity for BACE1. More specifically, the invention provides monoclonal antibodies that bind to BACE1 and are capable of inhibiting the activity of BACE1 and methods producing these antibodies. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: February 17, 2015
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U.Leuven R&D
    Inventors: Bart De Strooper, Lujia Zhou, Wim Annaert
  • Patent number: 8790887
    Abstract: The invention relates to the field of disorders of the peripheral or central nervous system, in particular, Alzheimer's disease, and the prevention and/or treatment thereof. In particular, the invention relates to ARF6 and/or ARF6 effector proteins as new targets in Alzheimer's disease, and based thereon, screening methods for compounds that reduce amyloid beta peptide formation in mammalian cells by affecting ARF6-mediated endosomal sorting.
    Type: Grant
    Filed: December 6, 2010
    Date of Patent: July 29, 2014
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Wim Annaert, Ragna Sannerud, Katrijn Coen, Bart De Strooper
  • Patent number: 8580493
    Abstract: The invention relates to the field of disorders of the peripheral or central nervous system, in particular, Alzheimer's disease, and the prevention and/or treatment thereof. In particular, the invention relates to the screening of compounds that modulate GPR3 activity and/or beta-arrestin signaling in a mammalian cell and, in particular, compounds that reduce the formation of amyloid beta peptides. The invention also relates to inhibiting agents targeting beta-arrestin signaling and pharmaceutical compositions thereof, and their use in therapeutic applications of those disorders.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: November 12, 2013
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Bart De Strooper, Amantha Thathiah
  • Patent number: 8568717
    Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: October 29, 2013
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R&D, Vrije Universiteit Brussel
    Inventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
  • Publication number: 20120276076
    Abstract: The invention relates to the field of disorders of the peripheral or central nervous system, in particular, Alzheimer's disease, and the prevention and/or treatment thereof. In particular, the invention relates to ARF6 and/or ARF6 effector proteins as new targets in Alzheimer's disease, and based thereon, screening methods for compounds that reduce amyloid beta peptide formation in mammalian cells by affecting ARF6-mediated endosomal sorting.
    Type: Application
    Filed: December 6, 2010
    Publication date: November 1, 2012
    Applicants: KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D, VIB VZW
    Inventors: Wim Annaert, Ragna Sannerud, Katrijn Coen, Bart De Strooper
  • Publication number: 20120237526
    Abstract: The present invention relates to antibodies with a specificity for BACE1. More specifically, the invention provides monoclonal antibodies that bind to BACE1 and are capable of inhibiting the activity of BACE1 and methods producing these antibodies. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.
    Type: Application
    Filed: June 15, 2010
    Publication date: September 20, 2012
    Applicants: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D
    Inventors: Bart De Strooper, Lujia Zhou, Wim Annaert
  • Publication number: 20120136045
    Abstract: The invention relates to the field of disorders of the peripheral or central nervous system, in particular, Alzheimer's disease, and the prevention and/or treatment thereof. In particular, the invention relates to the screening of compounds that modulate GPR3 activity and/or beta-arrestin signaling in a mammalian cell and, in particular, compounds that reduce the formation of amyloid beta peptides. The invention also relates to inhibiting agents targeting beta-arrestin signaling and pharmaceutical compositions thereof, and their use in therapeutic applications of those disorders.
    Type: Application
    Filed: June 4, 2010
    Publication date: May 31, 2012
    Applicants: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Bart De Strooper, Amantha Thathiah
  • Publication number: 20110091446
    Abstract: The present invention relates to single domain antibodies with a specificity for BACE1. More specifically, the invention provides single variable domain antibodies derived from camelids which bind to BACE1 and are capable of inhibiting the activity of BACE1. Said antibodies can be used for research and medical applications. Specific applications include the use of BACE1 specific antibodies for the treatment of Alzheimer's disease.
    Type: Application
    Filed: April 3, 2009
    Publication date: April 21, 2011
    Applicants: KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D, VRIJE UNIVERSITEIT BRUSSEL
    Inventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
  • Publication number: 20110008350
    Abstract: The present invention relates to the field of neurological disorders and more particularly to the field of Alzheimer's disease. Specifically, the invention provides extracellular targets for Alzheimer's disease selected from the tetraspanin web family and associated proteins. In addition, methods are provided for the use of siRNAs and antibodies against the targets for inhibition of amyloid-beta production and, hence, for the treatment of Alzheimer's disease.
    Type: Application
    Filed: October 3, 2008
    Publication date: January 13, 2011
    Inventors: Bart De Strooper, Tomoko Wakabayashi
  • Publication number: 20100204309
    Abstract: The invention relates to the identification of microRNAs whose expression is diminished in neurodegenerative disorders. In particular, the identified microRNAs can be used for the downregulation of the beta-secretase (BACE1) in mammalian brain and hence for the treatment of Alzheimer's disease.
    Type: Application
    Filed: April 21, 2008
    Publication date: August 12, 2010
    Applicants: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R & D
    Inventors: Sébastien Hérbert, Bart De Strooper
  • Publication number: 20100093001
    Abstract: The present invention relates to the field of amyloid disorders, more particularly to the field of diseases where protein misfolding leads to the generation of insoluble amyloid fibers in tissues and organs. The invention provides methods for the production of soluble, toxic amyloid oligomers. The invention further provides assays using the amyloid oligomers to screen for molecules that interfere with the toxicity of the oligomers.
    Type: Application
    Filed: September 6, 2007
    Publication date: April 15, 2010
    Inventors: Frederic Rousseau, Joost Schymkowitz, Ivo da Rocha Martins, Bart De Strooper
  • Publication number: 20080120731
    Abstract: The current invention relates to the field of neurodevelopmental disorders and more particularly to the field of neuropsychiatric disorders. The invention provides non-human, transgenic animal models for said neurodevelopmental disorders such as schizophrenia, bipolar disorders, compulsive disorders and the like. The animals also have applications in the field of Alzheimer's Disease and other disorders in which ?-secretase activity has a role.
    Type: Application
    Filed: December 13, 2005
    Publication date: May 22, 2008
    Inventors: Bart De Strooper, Tim Dejaegere, Ludgarde Serneels
  • Patent number: 7198903
    Abstract: The present invention relates to the identification of the molecular binding domains between presenilins and its substrates such as amyloid precursor protein and telencephalin. These binding domains can be efficiently used in drug screening assays to screen for compounds capable of modulating the interaction between presenilins and type I transmembrane proteins. The invention further relates to compounds capable of modulating the interaction.
    Type: Grant
    Filed: September 15, 2003
    Date of Patent: April 3, 2007
    Assignee: Vlaams Interuniversitair Instituut voor Biotechnologie VZW
    Inventors: Bart De Strooper, Wim Annaert